HGH Fragment 176-191

They are close relatives. Fragment 176-191 is the unmodified C-terminal segment of hGH. AOD-9604 is the 177-191 sequence with a tyrosine added at the N-terminus to improve stability, which is why it was the version taken into formal human trials. They share the same lipolytic domain and mechanism, so most of the published research (Ng, Heffernan) applies to both. In practice, the fragment is the raw peptide and AOD-9604 is the engineered, trial-tested analog.

Full growth hormone binds the GH receptor and drives growth, IGF-1 production, and insulin antagonism alongside its fat-mobilizing effect. Fragment 176-191 is only the fat-mobilizing tail. Published studies show it stimulates lipolysis and reduces lipogenesis without engaging the GH receptor, without raising IGF-1, and without the hyperglycemia associated with GH [2,4]. You get the lipolytic action isolated from the anabolic and metabolic baggage.

Honestly, the human evidence is weak. The animal data (obese mice and Zucker rats) show real reductions in body-weight gain and increased fat oxidation [3,5], but that has not translated cleanly to people. The stabilized analog AOD-9604 went through a 24-week Phase 2 obesity trial and did not produce significant weight loss versus placebo, and Fragment 176-191 itself has no controlled human efficacy data. Treat any fat-loss claim as unproven in humans.

Common research protocols use 250-500mcg subcutaneously per day, sometimes split into two doses. It is frequently administered on an empty stomach or before fasted cardio, on the rationale that low circulating insulin favors lipolysis. Dosing is empirical: there are no human dose-response trials for the fragment, so protocols are extrapolated from the AOD-9604 and rodent literature.

Bacteriostatic water is the standard diluent. For a 5mg vial, 2mL of BAC water yields 2.5mg/mL (so 250mcg = 0.1mL and 500mcg = 0.2mL). Add the water slowly down the vial wall, swirl gently, and never shake. Refrigerate after reconstitution and protect from light.

Researchers commonly investigate it alongside CJC-1295, Ipamorelin, or GLP-1 agonists. The mechanisms are complementary: GH secretagogues raise endogenous GH pulses, GLP-1 agonists cut caloric intake centrally, and Fragment 176-191 acts locally on adipocytes to mobilize fat without touching appetite or the GH receptor. Because it does not raise IGF-1 or glucose, it layers onto these protocols without adding their metabolic effects.